$AIM Just so I understand: AIM keeps its stock from tanking by announcing preliminary trial after preliminary trial -- but never any detailed or meaningful results. Then they cancel a bunch of those studies and tell us that that's actually good for investors -- still without even announcing detailed results from the pancreatic cancer study they've been promising but sitting on for months. All the while, Tom gets to play with his horsies, pretending to be some super CEO. Sounds like straight up fraud, and like AIM needs to be sued by shareholders. Again. What a steaming POS. I mean Tom. But also the stock.
2
8
8 Likes